What is the Fiscal Year for IceCure Medical?

Headquarters

Caesarea, Israel

Industry

Manufacturing, Medical Equipment

Stock Symbol

ICCM

Website

Description

IceCure Medical is a medical device company dedicated to providing patients and healthcare providers with the minimally invasive choice of cryoablation using liquid nitrogen for the treatment of benign and cancerous tumors. Our flagship device, the ProSense System, utilizes the power of liquid nitrogen to generate ultra-cold temperatures quickly to create large lethal zones that freeze and destroy tumors. By using liquid nitrogen, the system enables procedures to be performed in office-based settings, as there is no need for special safety precautions compared to other high-pressure gases used in cryoablation such as argon. In 2024, IceCure completed the ICE3 Clinical Trial – the largest controlled multi-location clinical trial ever completed for cryoablation of low-risk, early-stage breast cancer without excision. The trial has shown promising results with 96.3% of patients free from local recurrence when treated with ProSense Cryoablation and endocrine therapy. 100% of patients and doctors reported satisfaction with the procedure. There is minimal pain associated with the procedure and a rapid recovery. The treatment provides excellent cosmetic results with minimal scarring or change in the shape of the breast. Supported by a wide array of clinical experience in tumors of the breast, kidney, thoracic surgery, and musculoskeletal lesions* and backed by multiple independent studies, our FDA-cleared and CE-marked ProSense System offers proven and convenient treatments so patients can freeze their cancer, not their life. * IceCure Medical LTD’s ProSense™ Cryoablation System has worldwide distribution. Please check that the clinical indications for use discussed herein are cleared for use in your country.